Research ArticleCancer

Irreversible inhibition of cytosolic thioredoxin reductase 1 as a mechanistic basis for anticancer therapy

See allHide authors and affiliations

Science Translational Medicine  14 Feb 2018:
Vol. 10, Issue 428, eaaf7444
DOI: 10.1126/scitranslmed.aaf7444

Article Information

vol. 10 no. 428

PubMed: 
Print ISSN: 
Online ISSN: 
History: 
  • Received for publication March 23, 2016
  • Resubmitted February 1, 2017
  • Accepted for publication December 14, 2017
  • .

Author Information

  1. William C. Stafford1,2,
  2. Xiaoxiao Peng1,*,
  3. Maria Hägg Olofsson3,,
  4. Xiaonan Zhang3,
  5. Diane K. Luci4,
  6. Li Lu5,
  7. Qing Cheng1,
  8. Lionel Trésaugues6,,
  9. Thomas S. Dexheimer4,§,
  10. Nathan P. Coussens4,,
  11. Martin Augsten3,,**,
  12. Hanna-Stina Martinsson Ahlzén1,††,
  13. Owe Orwar2,7,
  14. Arne Östman3,8,
  15. Sharon Stone-Elander9,10,
  16. David J. Maloney4,‡‡,
  17. Ajit Jadhav4,
  18. Anton Simeonov4,
  19. Stig Linder3,11 and
  20. Elias S. J. Arnér1,§§
  1. 1Division of Biochemistry, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, SE 171 77 Stockholm, Sweden.
  2. 2Oblique Therapeutics AB, SE 413 46 Gothenburg, Sweden.
  3. 3Department of Oncology-Pathology, Karolinska Institutet, SE 171 77 Stockholm, Sweden.
  4. 4NIH Chemical Genomics Center, National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, MD 20892–4874, USA.
  5. 5Karolinska Experimental Research and Imaging Center, Karolinska University Hospital, SE 171 76 Stockholm, Sweden.
  6. 6Division of Biophysics, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, SE 171 77 Stockholm, Sweden.
  7. 7Department of Physiology and Pharmacology, Karolinska Institutet, SE 171 77 Stockholm, Sweden.
  8. 8University of Bergen, Postboks 7804, N-5020 Bergen, Norway.
  9. 9Department of Neuroradiology, Positron Emission Tomography Radiochemistry, Karolinska University Hospital, SE 171 76 Stockholm, Sweden.
  10. 10Department of Clinical Neurosciences, Karolinska Institutet, SE 171 77 Stockholm, Sweden.
  11. 11Division of Drug Research, Department of Medicine and Health, Linköping University, SE 581 83 Linköping, Sweden.
  1. §§Corresponding author. Email: elias.arner{at}ki.se
  • * Present address: Cardiovascular and Metabolic Diseases, Translational Medicine Unit, Early Clinical Development, Innovative Medicine and Early Development Biotech Unit, AstraZeneca, SE 431 83 Mölndal, Sweden.

  • Present address: VLVBio AB, SE 131 30 Nacka, Sweden.

  • Present address: Sprint Bioscience, Novum, SE 141 57 Huddinge, Sweden.

  • § Present address: Department of Pharmacology and Toxicology, Michigan State University, East Lansing, MI 48824, USA.

  • Present address: Division of Pre-Clinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, MD 20892–4874, USA.

  • Present address: amcure GmbH, 76344 Eggenstein-Leopoldshafen, Germany.

  • ** Division of Vascular Oncology and Metastasis, German Cancer Research Center, Heidelberg, Germany.

  • †† Present address: Clinical Immunology and Transfusion Medicine, Blood Component Unit, Karolinska University Hospital, Huddinge, SE 141 86 Stockholm, Sweden.

  • ‡‡ Present address: Inspyr Therapeutics Inc., Westlake Village, CA 91362, USA.

Altmetric

Article usage

Article usage: February 2018 to September 2019

AbstractFullPdf
Feb 20185212249558
Mar 201860771124
Apr 20183735558
May 20184494477
Jun 20184122649
Jul 20182143761
Aug 20182117160
Sep 20182023930
Oct 20182345251
Nov 20182666339
Dec 20182252930
Jan 20192233935
Feb 20199316347
Mar 20192433085
Apr 20191530097
May 20196278111
Jun 2019337491
Jul 20191353373
Aug 20199103239
Sep 2019169647

Navigate This Article